Mayo Clinic researchers have identified new scoring criteria allowing for the detection of treatable forms of rapidly progressive dementia (RPD) with reasonably high confidence during a patient’s first clinical visit. This scoring criteria may allow physicians to substantially reduce the time it takes to begin treatment. The findings are published in the Annals of Neurology.
Recent Posts
- Setting the standard: Tennessee Valley stem cell processing lab earns national accreditation
- Improving CAR-T therapy from within
- ‘A cure on the horizon’: Are we finally close to ending type 1 diabetes?
- Scientists create “smart” DNA drug that targets cancer cells with extreme precision
- Patient deaths prompt concern over regenerative care not covered by insurance
- Biotech IPOs Rebound as AI Takes a More Central Role in Drug Development


